A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011

Pharmaceuticals

Volumn 6, Issue 11, 2013, Pages 1335-1346

  Morrissey, Ian ^a   Hackel, Meredith ^b   Badal, Robert ^b   Bouchillon, Sam ^b   Hawser, Stephen ^a   Biedenbach, Douglas ^b  

^a International Health Management Associates Europe Sàrl   (Switzerland)

^b Division of Microbiology   (United States)

Author keywords

Carbapenems; Extended spectrum lactamase; Gram negative; Surveillance

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER CLOACAE; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MEDICAL RESEARCH; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; NONHUMAN; PREVALENCE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; REVIEW; STUDY FOR MONITORING ANTIMICROBIAL RESISTANCE TRENDS; TREND STUDY; URINARY TRACT INFECTION;

EID: 84887157965     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6111335     Document Type: Review

References (25)

1. Hawser, S. Surveillance programmes and antibiotic resistance: Worldwide and regional monitoring of antibiotic resistance trends. Antibiotic Resist. 2012, 211, 31-43.
2. Felmingham, D.; White, A.R.; Jacobs, M.R.; Appelbaum, P.C.; Poupard, J.; Miller, L.A.; Grüneberg, R.N. The Alexander Project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 2005, 56, ii3-ii21.
3. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards-Ninth Edition; CLSI document M07-A9; Clinical Laboratory Standards Institute: Wayne, PA, USA, 2012.
4. Performance Standards for Antimicrobial Susceptibility Testing, Twenty-second Informational Supplement; CLSI document M100-S23; Clinical and Laboratory Standards Institute (CLSI): Wayne, PA, USA, 2013.
5. Hawser, S.P.; Bouchillon, S.K.; Hoban, D.J.; Badal, R.E. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: Results from the SMART study. Int. J. Antimicrob. Agents. 2009, 34, 585-588.
6. Lascols, C; Hackel, M.; Hujer, A.M.; Marshall, S.H.; Bouchillon, S.K.; Hoban, D.J.; Hawser, S.P.; Badal, R.E.; Bonomo, R.A. Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: A snapshot of extended-spectrum β-lactamases throughout the world. J. Clin. Microbiol. 2012, 50, 1632-1639.
7. Hawser, S.P.; Bouchillon, S.K.; Lascols, C; Hackel, M.; Hoban, D.J.; Badal, R.E.; Woodford, N.; Livermore, D.M. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob. Agents Chemother. 2011, 55, 3917-3921.
8. Yong, D.; Toleman, M.A.; Giske, C.G.; Cho, H.S., Sundman, K.; Lee, K.; Walsh, T.R. Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 2009, 53, 5046-5054.
9. Castanheira, M.; Deshpande, L.M.; Mathai, D. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob. Agents Chemother. 2010, 55, 1274-1278.
10. Kumarasamy, K.K.; Toleman, M.A.; Walsh, T.R. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study. Lancet Infect. Dis. 2010, 10, 597-602.
11. Lascols, C; Hackel, M.; Marshall, S.H.; Hujer, A.M.; Bouchillon, S.; Badal, R.; Hoban, D.; Bonomo, R.A. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: Data from the SMART study (2009). J. Antimicrob. Chemother. 2011, 66, 1992-1997.
12. Sheng, W.H.; Badal, R.E.; Hsueh, P.R.; SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob. Agents Chemother. 2013, 57, 2981-2988.
13. Yang, Q.; Wang, H.; Chen, M.; Ni, Y.; Yu, Y.; Hu, B.; Sun, Z.; Huang, W.; Hu, Y.; Ye, H.; et al. Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002-2009 Study for Monitoring Antimicrobial Resistance Trends (SMART). Int. J. Antimicrob. Agents 2010, 36, 507-512.
14. Hawser, S.P.; Badal, R.E.; Bouchillon, S.K.; Hoban, D.J.; SMART India Working Group. Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008. J. Med. Microbiol. 2010, 59, 1050-1054.
15. Hawser, S.P.; Badal, R.E.; Bouchillon, S.K.; Hoban, D.J. Trending eight years of in vitro activity of ertapenem and comparators against Escherichia coli from intra-abdominal infections in North America-SMART 2002-2009. J. Chemother. 2011, 23, 266-272.
16. Brink, A.J.; Botha, R.F.; Poswa, X.; Senekal, M.; Badal, R.E.; Grolman, D.C.; Richards, G.A.; Feldman, C.; Boffard, K.D. Veller, M.; et al. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): Impact of the new carbapenem breakpoints. Surg. Infect. 2012, 13, 43-49.
17. Yang, Q.; Zhang, H.; Wang, Y.; Xu, Y.; Chen, M.; Badal, R.E.; Wang, H.; Ni, Y.; Yu, Y.; Hu, B.; et al. A ten-year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China. J. Med. Microbiol. 2013, 62, 1343-1349.
18. Hawser, S.P.; Badal, R.E.; Bouchillon, S.K.; Hoban, D.J.; Biedenbach, D.J.; Cantón, R. Paterson, D.L. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int. J. Antimicrob. Agents 2013, 41, 224-228.
19. Hoban, D.J.; Lascols, C.; Nicolle, L.E.; Badal, R.; Bouchillon, S.; Hackel, M.; Hawser, S. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum β-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: Results from the SMART study 2009-2010. Diagn. Microbiol. Infect. Dis. 2012, 74, 62-67.
20. Bouchillon, S.K.; Badal, R.E.; Hoban, D.J.; Hawser, S.P. Antimicrobial Susceptibility of Inpatient Urinary Tract Isolates of Gram-Negative Bacilli in the United States: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009-2011. Clin. Ther. 2013, 35, 872-877.
21. Hawser, S.P.; Bouchillon, S.K.; Hoban, D.J.; Badal, R.E. Epidemiologic trends, occurrence of extended-spectrum β-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002-2007 from the SMART study. Surg. Infect. 2010, 11, 371-378.
22. Babinchak, T.; Badal, R.; Hoban, D.; Hackel, M.; Hawser, S.; Lob, S.; Bouchillon, S. Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn. Microbiol. Infect. Dis. 2013, 76, 379-381.
23. Performance Standards for Antimicrobial Susceptibility Testing, Twenty-second Informational Supplement; CLSI document M100-S20U; Clinical Laboratory Standards Institute: Wayne, PA, USA, 2010.
24. Badal, R.E.; Lewis, J.S.; Motyl, M.R. Changes in the CLSI Interpretive Criteria for Enterobacteriaceae and Ertapenem. Clin. Microbiol. Newsl. 2011, 33, 185-186.
25. Performance Standards for Antimicrobial Susceptibility Testing, Twenty-second Informational Supplement; CLSI document M100-S22; Clinical and Laboratory Standards Institute (CLSI): Wayne, PA, USA, 2012.